Dimerix Limited confirmed that the CLARITY 2.0 investigator-led study of DMX-200 in COVID-19 patients has reported top line data. In total, 49 patients were recruited into the study, with 25 receiving DMX-200 and 24 receiving a placebo for 28 days. All patients were treated concurrently with an angiotensin receptor blocker (ARB).

Protocol adherence was high and medication adherence complete. DMX-200 appeared to be safe and well-tolerated, with no notable variation in the incidence or severity of adverse events between treatment with DMX-200 or placebo. There were no serious adverse events related to the drug reported.

The safety data findings are entirely consistent with existing and growing strong safety profile of DMX-200. The cohort was low risk, highly vaccinated and with high rates of other COVID-19 treatments. The median age was 37 years and 92% had received prior COVID-19 vaccination.

In addition, 69% of patients received concomitant corticosteroid treatment, a therapy now proven effective in the treatment of hospitalised COVID-19.